Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT522

Cell therapy (NK cells) · Kills target cells, directed at CD19 · developed by Fate Therapeutics

Phase 1 Most advanced trial (none active)
FATE Developer
1 Registered trials

What is FT522?

FT522 is an allogeneic, iPSC-derived natural killer cell product engineered to express an anti-CD19 chimeric antigen receptor, a high-affinity CD16 Fc receptor, an IL-15 fusion, and an alloimmune defense receptor targeting 4-1BB, with CD38 expression eliminated. It kills CD19-expressing tumor cells and is being studied in relapsed or refractory B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Targets
CD19 (antigen), 4-1BB (CD137) (TNFRSF9) (secondary target)
Mechanism
Kills target cells, directed at CD19
Pathways
NK cell survival and cytotoxicity, T-cell activation and recruitment via cytokine and chemokine secretion
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05950334 Phase 1 Relapsed/Refractory B-Cell Lymphoma Completed FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory B-Cell Lymphoma

Other drugs acting on CD19

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT522

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.